期刊文献+

脂蛋白(a)颗粒和质量浓度在评价冠状动脉粥样硬化斑块性质中的临床应用 被引量:11

The application of particle concentration or mass concentration of lipoprotein (a) in the evaluation of coronary artery plaques characteristics
原文传递
导出
摘要 目的探讨血清脂蛋白(a)[LP(a)]在评价冠状动脉粥样硬化性心脏病(CAHD)患者冠状动脉斑块性质的临床应用价值。方法采用病例对照研究,选取2013年10月至2015年6月在上海市东方医院进行冠状动脉CT血管造影(CTA)检查的患者790例,依冠状动脉CTA的结果分为CAHD组(352例)和正常对照组(438名),CAHD组据斑块性质不同分为软斑块176例、钙化斑块90例和混合斑块86例,检测LP(a)[颗粒数(P)和质量(M)]浓度、甘油三酯(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL—C)、低密度脂蛋白胆固醇(LDL—C)、葡萄糖、糖化血红蛋白A1c(HBA1c)和超敏C反应蛋白(hs—CRP)等指标,并进行综合分析。各组均数比较采用t检验或方差分析;各指标对CAHD风险估计采用Logistie回归,LP(a)-P和LP(a)-M进行直线回归,一致性分析使用Kappa检验。结果CAHD组和对照组比较,LP(a)-P18.5(8.3—43.0)nmol/L与13.6(7.6~32.4)nmol/L(t=-2.110)和LP(a)-M183(71~361)mg/L与126(67~293)mg/L(t=-2.063)、年龄(62±9)岁与(52±9)岁(t=-7.691)、hs—CRP0.86(0.44~1.97)mg/L与0.70(0.38—1.64)mg/L(t=-2.236)、葡萄糖(6.10±2.29)mmol/L与(5.36±1.32)mmol/L(t=-4.914)、HBA1c(6.13±0.98)%与(5.81±0.58)%(t=-4.842)、APO(B)(1.09±0.33)g/L与(1.03±0.29)g/L(t=-2,407),CAHD组均明显高于对照组(P均〈0.05);年龄、葡萄糖、LP(a)-P和LP(a)-M对CAHD的相对危险度分为1.067、2.377、1.384和1.342。斑块性质组间比较。年龄、TC、HDL-12、LDL—c和LP(a)-P组均数差异有统计学意义(F分别是6.276,3.060,3.127,4.723,2.878;P均〈0.05);LP(a)-P在软斑块组中位数20.3(8.3—48.2)nmol/L高于混合斑块组15.7(7.3~26.0)nmol/L(P〈0.05)和钙化组15.6(8.1-23.1)nmol/L(P〈0.05)。LP(a)-M对LP(a)-P的直线回归方程为Y=6.646X,r=0.939;一致性检验认为两种方法对个体分组不一致(Kappa值为0.557)。结论血清LP(a)浓度升高是患CAHD的危险因素之一,LP(a)颗粒数浓度升高与冠状动脉斑块性质尤其是软斑块高度相关。 Objective To investigate the clinical value of serum lipoprotein (a) concentration in evaluation of plaques characteristics for patients with coronary atherosclerotic heart diseases (CAHD). Methods Using case-control method, Patients with suspicious CAHD, received coronary, computed tomography angiography in the Shanghai East Hospital during October 2013 to June 2015 were enrolled. According to the results of coronary artery CTA, the patients were divided into two groups : the CAHD group (352 cases) and control group(438 cases) , the particle concentrations and mass concentration of lipoprotein(a) , triglyceride, total cholesterol, HDL-C, LDL-C, glucose, HBAlc and hs-CRP and other tests were measured, the patients of CAHD group were divided into three subgroups by characteristics of coronar7 artery plaques including soft plaque (176 cases) , calcified plaque (90 cases ) and mixed plaque (86 cases), analysis were made with all these data. Using T test or variance analysis to compare the means between or among groups, the risk for CAHD was analyzed by logistic regression, the relationship between LP (a) -P and LP(a) -M were explored by linearly egression analysis, Conformance test were analyzed using kappa test. Results Compared with control group, the mean results of the CAHD group are significantly higher than that of control group, including LP (a) -P 18.5 (8.3 - 43.0) ) mnol/L vs. 13.6 (7.6-32.4)nmol/L( t = -2.110), LP(a)-M 183(71 -361)mg/L vs. 126(67-293)mg/L(t = -2. 063), age (62 ±9)years vs. (52 ±9)years(t = -7. 691), hs-CRP 0. 86(0. 44 - 1.97) )mg/L vs. 0.70 (0. 38 - 1.64) rag/L( t = - 2. 236) , glucose (6. 1 ± 2.29 ) mmol/L vs. (5.3± 1.32 ) mmol/L ( t = -4.914), BAIc (6.13±0.98) % vs. (5.81±0.58) %(t= -4.842), APO(B) (1.09±0.33) g/L vs. ( 1. 03 ±0. 29) g/L( t = -2. 407) , all of the P values 〈0. 05; The relative risk(RR)of age, glucose, LP( a)-P and LP(a)-M are 1.067, 2. 377, 1. 384 and 1. 342 respectively; Among the three types of plaques groups,the mean differences of age, TC, HDL-C, LDL-C and LP (a)-P are statistically significant ( F = 6. 276,3. 060,3. 127,4. 723,2. 878; all of the P 〈 0. 05) ; The median of LP (a) -P in the soft plaque group 20.3 ( 8.3 - 48.2) nmol/L is higher than that of the mixed plaque group 15.7 (7.3 - 26.0) nmoUL ( P 〈0. 05 ) and calcified plaque group 15.6 ( 8.1 - 23.1 ) nmol/L ( P 〈 0. 05 ). The linearly regression equation of LP (a) -M and LP(a)-P is Y = 6. 646X, r = 0. 939; Consistency test indicate the two methods are not consistent when used for grouping ( Kappa value is 0. 557 ). Conclusions Serum concentration of lipoprotein(a) is an independent risk factor of CAHD, and the particle concentration of LP(a) is closely related to the characteristics of the plaques, especially to the soft plaque.
出处 《中华检验医学杂志》 CAS CSCD 北大核心 2016年第3期215-219,共5页 Chinese Journal of Laboratory Medicine
关键词 动脉粥样硬化 脂蛋白(A) 冠状血管造影术 Atherosclerosis Lipoprotein(a) Coronary angiography
  • 相关文献

参考文献14

  • 1Mareovina SM, Koschinsky ML. Lipoprotein(a) as a risk factor for coronary artery disease [ J ]. Am J Cardiol, 1998,82 (12A) : 57U-66U. DOI : 10. 1016/S0002-9149 (98) 00954-0.
  • 2Kronenberg F, Utennann G. Lipoprotein ( a ) : resurrected by genetics[ J]. J Intern Med,2013,273 (1) :6-30. DOI: 10.1186/ 1476-51 lx-11-128. DOI:10. 1 lll/j. 1365-2796. 2012. 02592. x.
  • 3Hoover-Plow J, Huang M. Lipoprotein (a) metabolism : potential sites for therapeutic targets [ J ]. Metabolism, 2013,62 ( 4 ) : 479- 491. DOI: 10. 1016/i. metabol. 2012.07. 024.
  • 4卫生部.冠状动脉粥样硬化性心脏病诊断标准[S].WS319-2010,2010.
  • 5Dub6 B, Boffa MB, Hegele RA, et al. Lipoprotein (a) : more interesting than ever 'after 50 years[J]. Curr Opin Lipidol,2012, 23(2) :133-140. DOI: 10. 1097/MOL. 0bO13e32835111 d8.
  • 6Kurt B, Soufi M, Sattler A, et al. Lipoprotein (a)-clinical aspects and future challenges[ J]. Clin Res Cardiol Suppl,2015, 10(snppl) :26-32. DOI : 10. 1007/s11789-015-0075-z.
  • 7NoMestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status [J]. Eur Heart J,2010, 31 (23) :2844-2853. DOI: 10. 1093/eurhearti/eha386.
  • 8莫海泉,赵建萍,黄自明.hs-CRP、LP(a)在急性冠脉综合征患者临床危险分层中的应用[J].广东医学院学报,2015,33(3):283-284. 被引量:6
  • 9Kamstrup PR, Tybjerg-Hansen A, Nordestgaard BG. Extreme Lipoprotein (a) Levels and Improved Cardiovascular Risk Prediction[ J]. J Am Coll Cardiol, 2013,61 ( 11 ) : 1146-1156. DOI: http ://dx. doi. org/10. 1016/j. jace. 2012. 12. 023.
  • 10徐宝华,赵慧颖.动脉粥样硬化不稳定斑块的研究进展[J].心血管病学进展,2005,26(5):498-501. 被引量:23

二级参考文献70

  • 1李建军,李庚山.动脉粥样斑块破裂的研究进展[J].中华老年心脑血管病杂志,2000,2(4):273-278. 被引量:23
  • 2孟存良,齐晓勇,赵勇军,谷剑,李树仁,李英肖.同型半胱氨酸血症与冠心病患者冠脉病变稳定性及病变程度关系研究[J].河北医科大学学报,2006,27(3):170-173. 被引量:12
  • 3李雷,李东野,夏勇,钱文浩,徐通达,陈清枝.血浆同型半胱氨酸水平与冠心病的关系[J].心脏杂志,2006,18(3):365-365. 被引量:3
  • 4吴惠玲,何国祥,刘建平,冉擘力,李永华,仝识非,姚青,唐波.血浆超敏C反应蛋白水平与冠心病及粥样斑块的关系[J].临床心血管病杂志,2006,22(7):405-407. 被引量:30
  • 5Cercek B,Yamashita M,Dimayuga P,et al.Nuclear factor-κB activity and arterial response to balloon injury[J].Atherosclerosis,1997,131:59-66.
  • 6Ridker PM,Rifai N,Pfeffer MA,et al.Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesterol levels[J].Circulation,1998,98:839-844.
  • 7George S,Abela MD,Paulo D,et al.Triggering of plaque disruption and arterial thrombosis in an atherosclerotic rabbit model[J].Circulation,1995,91:776-784.
  • 8Mann JM,Davies MJ.Vulnerable plaque.Relation of characteristics to degree of stenosis in human coronary arteries[J].Circulation,1996,94(5):928-931.
  • 9Zhang SH,Reddick RL,et al.Spontaneous Hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E[J].Science,1992,258(10):468-471.
  • 10Bhatia V,Bhatia R.Imaging of the vulnerable plaque:new modalities[J].South Med J,2003,96(11):1142-1147.

共引文献35

同被引文献97

  • 1李庆,王聪霞,董新,韩振华,魏瑾,张春艳,张岩,路艳,张荣,丁抗宁.血清胱抑素C、高敏C反应蛋白与冠状动脉粥样硬化斑块负荷的关系[J].西安交通大学学报(医学版),2012,33(1):43-47. 被引量:17
  • 2赵建国,高长玉,顼宝玉,孙怡,韩景献.脑梗死和脑出血中西医结合诊断标准(试行)[J].中国中西医结合杂志,2006,26(10):948-949. 被引量:553
  • 3李秋兰,李永余,陈晓婷,刘云高,李雅贞,陈辉兰,林惠.肝素锂抗凝血浆与蛇毒促凝血清在罗氏模块中的应用比较[J].国际检验医学杂志,2008,29(1):4-7. 被引量:2
  • 4Fernandez-Laso V,Sastre C,Valdivielso JM,et al. Soluble TWEAKlevels predict the presence of carotid atherosclerotic plaques insubjects free from clinical cardiovascular diseases[J]. Atherosclerosis,2015,239(2):358-63.
  • 5Tarin C,Carril M,Martinventura JL,et al. Targeted gold-coated ironoxide nanoparticles for CD163 detection in atherosclerosis by MRI[J].Scientific Reports,2015,36(6):90-4.
  • 6Turkmen K,Tonbul HZ,Erdur FM,et al. Soluble TWEAK independentlypredicts atherosclerosis in renal transplant patients[J]. BmcNephrology, 2013,26(4):102-4.
  • 7Sastre C,Fernández-Laso V,Madrigal-Matute J,et al. Geneticdeletion or TWEAK blocking antibody administration reduceatherosclerosis and enhance plaque stability in mice[J]. Journal ofCellular & Molecular Medicine,2014,22(5):34-7.
  • 8Moreno JA,Ortegagómez A,Delbosc S,et al. In vitro and in vivoevidence for the role of elastase shedding of CD163 in humanatherothrombosis[J]. European Heart Journal,2012,25(5):46-9.
  • 9Masood A,Jafar S S,Akram Z. Serum high sensitivity C-reactiveprotein levels and the severity of coronary atherosclerosis assessedby angiographic gensini score[J]. Journal of the Pakistan MedicalAssociation,2011,61(4):325-7.
  • 10李方去,丁红香,鲁勇.不同系统间C反应蛋白测定结果的比对和偏倚评估[J].中国卫生检验杂志,2009,19(9):2079-2080. 被引量:6

引证文献11

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部